Aptalis Holdings offcially withdraws IPO following announcement of acquisition by Forest Labs

Aptalis Holdings, which develops and markets therapies for cystic fibrosis and gastrointestinal disorders, withdrew its plans for an initial public offering on Friday. The company scrapped its IPO plans earlier this month with its announcement that it had reached an agreement to be acquired by Forest Laboratories for $2.9 billion.

The Bridgewater, NJ-based company was founded in 1982 and booked $688 million in sales for the 12 months ended September 30, 2013. Aptalis Holdings initially filed confidentially on November 4, 2013. Goldman Sachs and J.P. Morgan were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.